Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Brawn Biotech Ltd Performance

Today's Low
25.65
arrowIcon
Today's High
27.00
52 Wk Low
14.36
arrowIcon
52 Wk High
27.37


Open

25.65

Traded Value (Cr)

8.17 K

Prev. Close

27

VWAP

25.98

Volume

312.00

Face Value

10

Brawn Biotech Ltd Fundamentals

Market Cap
₹ 7 Cr
P/E Ratio (TTM)
42.21
P/B Ratio
2.62
Debt to Equity
0.00
ROE
0.00 %
EPS (TTM)
0.62
Dividend Yield
0.00%
Book Value
10.00

Click here to know more about Fundamentals

Brawn Biotech Ltd Financials

Brawn Biotech Ltd Financials

Brawn Biotech Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 53.64 % 53.72 % 53.72 % 53.72 %
Retail 33.91 % 42.90 % 42.89 % 42.87 %
Others 12.10 % 2.79 % 2.80 % 2.82 %
Mutual Funds 0.35 % 0.59 % 0.59 % 0.59 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

53.64%

Retail

33.91%

Others

12.10%

Mutual Funds

0.35%

FII

0.00%

Promoters

53.72%

Retail

42.90%

Others

2.79%

Mutual Funds

0.59%

FII

0.00%

Promoters

53.72%

Retail

42.89%

Others

2.80%

Mutual Funds

0.59%

FII

0.00%

Promoters

53.72%

Retail

42.87%

Others

2.82%

Mutual Funds

0.59%

FII

0.00%

Resistance and Support

₹26.46

PIVOT

resistance-arrow
Resistance
First Resistance₹27.913
Second Resistance₹28.827
Third Resistance₹30.283
support-arrow
Support
First Resistance₹25.543
Second Resistance₹24.087
Third Resistance₹23.173

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day10,593
Week5,4535,453100.00
1 Month1,2611,261100.00
6 Months000.00

About Brawn Biotech Ltd

Brawn Biotech Ltd was originally incorporated in the name of Brawn Pharmaceuticals Limited in November, 1985. Thereafter, the name of the Company was changed from Brawn Pharmaceuticals Limited to Brawn Biotech Limited in November, 2010. Brawn , with its inception barely 38 years back has today evolved into a fully integrated, healthcare group, marking its presence in India and across the globe. The Company possess product registration with major health and govt. institutions throughout India and worldwide. Headed and represented by a team of skilled industry experts with impressive educational backgrounds and broad experience, the Company has spread its wings in expansion in the domestic as well as in the international markets beyond the existing horizon to stand among the leading Indian HealthCare products distribution Companies. The Company is trading in Herbals, Ayurvedic and Critical Care range of Products along with other pharmaceutical products and distributing them in the overseas market, resulting in tremendous growth in sale and profits of the Company. Presently, the Company is also acting as consignee agent for the supplies to Government Hospitals and institutions. The Company is into Wholesale of Pharmaceutical and Medical Goods. Their Pharmaceutical Products cover all major product segments like Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. Besides a professional and competent team that looks into administration, sales, marketing, maintenance, etc., Brawn is supported by a team of highly qualified and experienced consultants to gain an edge over the others in the market.

Managing Director

Founded

1985

NSE Symbol

Brawn Biotech Ltd Management

NameDesignation
Brij Bala Gupta.Director
Kanta TakkarIndependent Director
Subhash ChanderIndependent Director
Priyanka SharmaCompany Sec. & Compli. Officer

Brawn Biotech Ltd News

Brawn Biotech announces board meeting date
On 14 February 2024
Brawn Biotech reports standalone net loss of Rs 0.42 crore in the September 2023 quarter
Sales decline 62.42% to Rs 2.92 crore
Brawn Biotech to announce Quarterly Result
On 10 November 2023
Brawn Biotech to hold AGM
On 25 September 2023
Brawn Biotech reports standalone net loss of Rs 0.04 crore in the June 2023 quarter
Sales reported at Rs 0.12 crore
Brawn Biotech to conduct board meeting
On 9 August 2023
Brawn Biotech reports standalone net loss of Rs 0.61 crore in the March 2023 quarter
Sales rise 64.36% to Rs 4.75 crore
Brawn Biotech to discuss results
On 29 May 2023
Brawn Biotech reports standalone net loss of Rs 0.04 crore in the December 2022 quarter
Sales rise 149.41% to Rs 6.31 crore
Brawn Biotech to hold board meeting
On 14 February 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
ADANIENT₹ 3,15,409 Cr
₹ 2,790.25
(0.85 %)
110.94
AEGISCHEM₹ 20,331 Cr
₹ 591.80
(2.17 %)
46.08
CELLO₹ 18,674 Cr
₹ 877.55
(-0.27 %)
491.56
REDINGTON₹ 15,846 Cr
₹ 205.40
(1.33 %)
15.16
HONASA₹ 13,884 Cr
₹ 429.30
(0.26 %)
145.65

Brawn Biotech Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Brawn Biotech Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Brawn Biotech Ltd's share price is ₹26.17 as of May 6, 2024

Brawn Biotech Ltd's P/E ratio is 42.21 times as of May 6, 2024.

Brawn Biotech Ltd's most recent financial reports indicate a price-to-book ratio of 2.62, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Brawn Biotech Ltd's market is 8 Cr as on May 6, 2024.

The current financial records of Brawn Biotech Ltd show a 0.00% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a Brawn Biotech Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Brawn Biotech Ltd's 52-week high and low as of May 6, 2024 are ₹27 and ₹25.65 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Brawn Biotech Ltd stands at 53.64%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.